Human Genome Sciences (HGS) received a major boost to its cancer pipeline by initiating a Phase II trial of its human monoclonal antibody HGS-ETRI (mapatumumab) and also licensed rights to Aegera Therapeutics’ AEG40826 anticancer compound and backup compounds.